Analyst Reco. Y-mAbs Therapeutics, Inc.

Equities

YMAB

US9842411095

Market Closed - Nasdaq Other stock markets 01:30:00 02/07/2024 am IST			5-day change	1st Jan Change
11.83 ^USD	-2.07%		-2.23%	+73.46%

01/07	Y-mAbs Therapeutics Appoints Peter Pfreundschuh as CFO	MT
01/07	Y-mAbs Therapeutics, Inc. Announces the Appointment of Peter Pfreundschuh as Chief Financial Officer	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Truist Initiates Y-mAbs Therapeutics at Buy With $21 Price Target, Calls Radioimmunotherapy Platform 'Undervalued'	28/06	MT
HC Wainwright Adjusts Price Target on Y-mAbs Therapeutics to $22 From $21, Keeps Buy Rating	06/03	MT
Canaccord Genuity Raises Price Target on Y-mAbs Therapeutics to $26 From $22, Maintains Buy Rating	04/03	MT
BMO Capital Adjusts Y-mAbs Therapeutics Price Target to $26 From $16, Maintains Outperform Rating	04/03	MT
Wedbush Raises Y-mAbs Therapeutics' PT to $23 From $18 After Higher-Than-Expected Q4 2023 Danyelza Net Product Revenue, Maintains Outperform Rating	04/03	MT
HC Wainwright Adjusts Y-mAbs Therapeutics Price Target to $21 From $11, Maintains Buy Rating	20/02	MT
Wedbush Raises Price Target on Y-mAbs Therapeutics to $18 From $12 After Plans for Phase 1 Cancer Drug Study, Keeps Outperform Rating	12/02	MT
Kempen Upgrades Y-mAbs Therapeutics to Buy From Neutral, Price Target is $10	22/12	MT
JPMorgan Adjusts Y-mAbs Therapeutics Price Target to $7 From $8, Maintains Underweight Rating	22/23/22	MT
Morgan Stanley Adjusts Price Target on Y-mAbs Therapeutics to $5 From $7, Maintains Underweight Rating	14/23/14	MT
Wedbush Trims Y-mAbs Therapeutics' Price Target to $12 From $13, Keeps Outperform Rating	11/23/11	MT
Canaccord Genuity Adjusts Y-mAbs Therapeutics' Price Target to $22 From $21, Keeps Buy Rating	25/23/25	MT
Morgan Stanley Adjusts Price Target on Y-mAbs Therapeutics to $7 From $4, Maintains Underweight Rating	10/23/10	MT
BMO Capital Raises Y-mAbs Therapeutics' Price Target to $15 From $13, Maintains Outperform Rating	10/23/10	MT
Wedbush Upgrades Y-mAbs Therapeutics to Outperform From Neutral, Notes Danyelza Return to Growth Trajectory; Raises PT to $13 From $5	10/23/10	MT
Canaccord Genuity Adjusts Y-mAbs Therapeutics Price Target to $21 From $18, Maintains Buy Rating	09/23/09	MT
HC Wainwright Lowers Price Target on Y-mAbs Therapeutics to $11 From $19, Maintains Buy Rating	04/23/04	MT
Guggenheim Downgrades Y-mAbs Therapeutics to Neutral From Buy	03/23/03	MT
Canaccord Genuity Adjusts Price Target on Y-mAbs Therapeutics to $18 From $20, Maintains Buy Rating	31/23/31	MT
BMO Capital Adjusts Price Target on Y-mAbs Therapeutics to $13 From $12, Maintains Outperform Rating	30/23/30	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Y-mAbs Therapeutics, Inc.

Equities

YMAB

US9842411095

Analyst Reco.

Filters